Document is current
Any future updates will be listed below
-
Authors
Sarasso, Elisabetta https://orcid.org/0000-0002-5300-2849
Gardoni, Andrea
Zenere, Lucia
Emedoli, Daniele https://orcid.org/0000-0002-7904-1803
Balestrino, Roberta
Grassi, Andrea
Basaia, Silvia
Tripodi, Chiara https://orcid.org/0009-0004-2638-736X
Canu, Elisa
Malcangi, Massimo
Pelosin, Elisa https://orcid.org/0000-0002-9880-2241
Volontè, Maria Antonietta
Corbetta, Davide https://orcid.org/0000-0003-3981-7248
Filippi, Massimo https://orcid.org/0000-0002-5485-0479
Agosta, Federica
-
Funding
Funding for this research was provided by:
Ministero della Salute (GR-2018-12366005)
- License Information
-
More Information
Article History
Received: 29 March 2024
Accepted: 20 August 2024
First Online: 6 September 2024
Competing interests
: E.S., A.G., L.Z., D.E., R.B., A.G., S.B., C.T., E.C., M.M., E.P., and M.A.V. declare no financial competing interests. D.C. is recipient of a grant form the Italian Ministry of Health. M.F. is Editor-in-Chief of the <i>Journal of Neurology</i>, Associate Editor of <i>Human Brain Mapping</i>, <i>Neurological Sciences</i>, and <i>Radiology</i>; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research and Fondazione Italiana Sclerosi Multipla. F.A. is Associate Editor of <i>NeuroImage: Clinical</i>, has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon and Eli Lilly, and receives or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme—Neurodegenerative Disease Research (JPND) and Foundation Research on Alzheimer Disease (France).
